Advances in Transdermal Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advances in Transdermal Technologies
Transdermal delivery takes up once-forbidden compounds, reviving markets and creating formulation opportunities.


Pharmaceutical Technology


Future prospects

There is much to look forward to for both passive and active transdermal drug delivery systems. "There is a huge opportunity for active diffusion as many products currently on the market are very difficult to deliver through passive diffusion. However, the passive diffusion market has certainly not been exhausted," says Myers. "Critical to the success of active diffusion is to develop products that are cost effective to the consumer."

Cirrus is exploring the use of nanotechnology in various areas of drug delivery and is capable of extending the technology to TDDS to improve skin permeation. Scientists at Adhesives Research are working on the development of a porous adhesive platform with tailorable pore sizes and densities that create pathways through which a drug may flow to the skin or moisture and other materials may be removed from the surface of the skin. The company also is developing coatings with molecularly imprinted polymers (MIPs). "These MIPs are synthesized with the unique chemical and physical 'imprint' of a target molecule. MIPs can be formulated into an adhesive coating and used to capture or release the target molecule in a diagnostic or drug delivery application," says Knorr.

"Where I see the technology going and where I see the market hasn't really expanded is partnerships with a pharmaceutical company to preload the devices with the drugs," says Duncan.

"We are at the forefront of what we can do," adds Pomonis. "We are clearly able to, with advances in microprocessors and electronics and circuitry, come up with very complex dosing regiments. We are understanding more and more about skin resistance and how that affects drug delivery. There are drugs sitting in the chemical libraries of pharmaceutical companies that have not made it through the development process either because of challenges in formulation or more likely worries about systemic side effects that may be addressed with advanced transdermal systems. Truly there should be a tremendous opportunity in the near future for those collaborations."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here